1243 related articles for article (PubMed ID: 11668468)
21. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma.
Park SY; Kim BH; Kim JH; Lee S; Kang GH
Arch Pathol Lab Med; 2007 Oct; 131(10):1561-7. PubMed ID: 17922593
[TBL] [Abstract][Full Text] [Related]
22. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas.
Bejarano PA; Baughman RP; Biddinger PW; Miller MA; Fenoglio-Preiser C; al-Kafaji B; Di Lauro R; Whitsett JA
Mod Pathol; 1996 Apr; 9(4):445-52. PubMed ID: 8729987
[TBL] [Abstract][Full Text] [Related]
23. Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors.
Tot T
Cancer; 1999 Jan; 85(1):171-7. PubMed ID: 9921990
[TBL] [Abstract][Full Text] [Related]
24. The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin.
Hecht JL; Pinkus JL; Weinstein LJ; Pinkus GS
Am J Clin Pathol; 2001 Oct; 116(4):483-8. PubMed ID: 11601132
[TBL] [Abstract][Full Text] [Related]
25. Histopathologic classification of lung cancer: Relevance of cytokeratin and TTF-1 immunophenotyping.
Johansson L
Ann Diagn Pathol; 2004 Oct; 8(5):259-67. PubMed ID: 15494931
[TBL] [Abstract][Full Text] [Related]
26. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.
Bayrak R; Haltas H; Yenidunya S
Diagn Pathol; 2012 Jan; 7():9. PubMed ID: 22268990
[TBL] [Abstract][Full Text] [Related]
27. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B.
Kaufmann O; Dietel M
Histopathology; 2000 Jan; 36(1):8-16. PubMed ID: 10632746
[TBL] [Abstract][Full Text] [Related]
28. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
McCluggage WG; Shah R; Connolly LE; McBride HA
Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
[TBL] [Abstract][Full Text] [Related]
29. The Value of Cytokeratin 5/6, p63 and Thyroid Transcription Factor-1 in Adenocarcinoma, Squamous Cell Carcinoma and Non-Small-Cell Lung Cancer of the Lung.
Argon A; Nart D; Veral A
Turk Patoloji Derg; 2015; 31(2):81-8. PubMed ID: 25944390
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma.
Saad RS; Cho P; Silverman JF; Liu Y
Am J Clin Pathol; 2004 Sep; 122(3):421-7. PubMed ID: 15362373
[TBL] [Abstract][Full Text] [Related]
31. Expression of cytokeratin 20 in mucinous bronchioloalveolar carcinoma.
Shah RN; Badve S; Papreddy K; Schindler S; Laskin WB; Yeldandi AV
Hum Pathol; 2002 Sep; 33(9):915-20. PubMed ID: 12378517
[TBL] [Abstract][Full Text] [Related]
32. CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall.
Mazziotta RM; Borczuk AC; Powell CA; Mansukhani M
Appl Immunohistochem Mol Morphol; 2005 Mar; 13(1):55-60. PubMed ID: 15722794
[TBL] [Abstract][Full Text] [Related]
33. Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas.
Bayrak R; Yenidünya S; Haltas H
Pathol Res Pract; 2011 Mar; 207(3):156-60. PubMed ID: 21282015
[TBL] [Abstract][Full Text] [Related]
34. Utility of a novel triple marker (combination of thyroid transcription factor 1, Napsin A, and P40) in the subclassification of non-small cell lung carcinomas using fine-needle aspiration cases.
Sharma R; Wang Y; Chen L; Gurda GT; Geddes S; Gabrielson E; Askin F; Li QK
Hum Pathol; 2016 Aug; 54():8-16. PubMed ID: 27045515
[TBL] [Abstract][Full Text] [Related]
35. Patterns of distribution of cytokeratins 20 and 7 in special types of invasive breast carcinoma: a study of 123 cases.
Tot T
Ann Diagn Pathol; 1999 Dec; 3(6):350-6. PubMed ID: 10594286
[TBL] [Abstract][Full Text] [Related]
36. [Value of cytokeratin 7 and 20 for the diagnosis of cerebral metastases of adenocarcinoma: study of 78 cases].
Fernandez C; Liprandi A; Bouvier-Labit C; Figarella-Branger D
Ann Pathol; 2001 Apr; 21(2):129-35. PubMed ID: 11373582
[TBL] [Abstract][Full Text] [Related]
37. Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction.
Shen B; Ormsby AH; Shen C; Dumot JA; Shao YW; Bevins CL; Gramlich TL
Cancer; 2002 Feb; 94(3):820-31. PubMed ID: 11857318
[TBL] [Abstract][Full Text] [Related]
38. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
Ciampa A; Fanger G; Khan A; Rock KL; Xu B
Cancer; 2004 Dec; 102(6):368-72. PubMed ID: 15558786
[TBL] [Abstract][Full Text] [Related]
39. The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms.
Chang YL; Lee YC; Liao WY; Wu CT
Lung Cancer; 2004 May; 44(2):149-57. PubMed ID: 15084379
[TBL] [Abstract][Full Text] [Related]
40. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies.
Goldstein NS; Thomas M
Am J Clin Pathol; 2001 Sep; 116(3):319-25. PubMed ID: 11554157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
